

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

TITLE

Beta-blocker exposure is associated with nonunion in a geriatric cohort of 253,266
extremity fractures

AUTHORS

Lillia Steffenson¹, Brook Martin¹, Adam Kantor¹, Dillon O'Neill¹, Luke Myhre¹, Tyler
Thorne¹, David Rothberg¹, Thomas Higgins¹, Justin Haller¹, Lucas Marchand¹

AFFILIATIONS

- 1. University of Utah

CORRESPONDING AUTHOR

Lillia Steffenson, MD
Department of Orthopaedics
University of Utah School of Medicine
590 Wakara Way
Salt Lake City, UT 84108
Phone: (801) 587-7100
Fax: 801-587-5411
E-mail: Lillia.Steffenson@hsc.utah.edu

Conflict of Interest: The authors have declared that no conflict of interest exists.

21 **ABSTRACT**

22 Previously published animal studies have shown positive skeletal effects with local or
23 systemic administration of beta blockers (BBs). However, population studies have
24 shown mixed effects on bone mineral density (BMD) and fracture risk with BB use. The
25 goal of this study was to evaluate whether exposure to BB is associated with fracture
26 nonunion. Fee-for-service Medicare beneficiaries with an extremity fracture were
27 identified by International Classification of Diseases (ICD)-10 and current procedural
28 terminology (CPT) codes from 2016-2019. Charlson Comorbidity Index (CCI) was
29 assigned using diagnoses prior to index fracture and nonunion identified by ICD-10 or
30 CPT codes within one year from index fracture diagnosis. Patients were classified by
31 BB exposure based on Part D (Pharmacy) claims between 90 days prior to and one
32 year following index fracture. Chi square and Student's T-tests were performed on
33 categorical and continuous variables, respectively. Logistic regression was performed to
34 evaluate the association between BB use and nonunion, controlling for age, sex, race,
35 and comorbidity. Total number of fractures meeting inclusion criteria was 253,266 with
36 45% of patients having used a BB during the study period. The incidence of nonunion
37 was 3.9% overall. BBs were associated with a 13% increase in non-union for all fracture
38 types, after controlling for age, sex, fracture location, and CCI (OR 1.13 [CI 1.06-1.20],
39 $p < .001$). Results of this study suggest a negative influence of BB on bone healing,
40 contrary to results of previously published animal models and epidemiologic
41 observations, and demonstrate that BB use during fracture care is associated with
42 significant increase in incidence of nonunion.

43

44 INTRODUCTION

45 Beta blockers are a class of medications which act as antagonists to beta-adrenergic
46 receptors of the sympathetic nervous system (SNS). These receptors are found
47 primarily in mesenchymal tissue types including cardiac, pulmonary, and vascular
48 smooth muscle as well as skeletal muscle, adipose and osseous tissue. There are three
49 subtypes of this adrenergic stimulated G-protein coupled receptor, beta-1, beta-2, and
50 beta-3 receptor, and effects vary due to the distribution of these receptors in different
51 tissues. Beta-1 receptors found within the heart increase heart rate and contractility
52 causing a rise in cardiac output while those in the kidneys promote renin secretion.
53 When stimulated, beta-2 receptors result in bronchodilation, vasodilation, and enhanced
54 skeletal muscle contraction in addition to gluconeogenesis and insulin secretion. Beta-3
55 receptors within fat tissue increases lipolysis and relaxation of bladder smooth muscle.
56
57 Skeletal homeostasis is maintained by the constant balance of activity between
58 osteoblasts (bone forming cells) and osteoclast (bone resorbing cells). This mechanism
59 may alter bone mineral density due to changes in activity or underlying physiologic
60 demands (1, 2). Within osseous tissue, beta-2 adrenergic receptors (β 2AR s) are found
61 on both osteoblasts and osteoclasts where β 2AR activation by norepinephrine and
62 epinephrine induces bone loss through RANK ligand-mediated activation of osteoclasts
63 and inhibits osteoblast proliferation (3). In mice, deletion of adrenergic beta-2 receptor
64 (*Adrb2*) leads to greater trabecular bone microarchitecture and bone mass within both
65 femur and vertebrae. Addition of beta-1 receptor knockout to the model results in loss

66 of this phenotype and overall decreased total bone volume and cortical thickness (4)
67 suggesting differential effects of these two receptor subtypes.

68
69 Observational studies in humans have similarly identified that individuals taking beta
70 blocker medications have higher bone mineral density (BMD) and lower fracture risk (5-
71 13). Considering post-menopausal women have been found to have higher sympathetic
72 activity compared to pre-menopausal women and sympathetic nerve activity is inversely
73 correlated with trabecular bone volume (14), these findings have renewed interest in
74 modulating adrenergic signaling as a potential intervention for primary osteoporosis
75 prevention (2). One such study by Khosla et al., saw increases in distal radius BMD in
76 post-menopausal women treated with 20 weeks of atenolol (15).

77
78 At present, there are no human studies evaluating the effect of beta blockers on fracture
79 outcome. However, in a murine fracture model, low dose propranolol over 9 weeks
80 increased periosteal and endosteal bone formation and improved consolidation of
81 fracture callus. In the absence of fracture, torsional strength of rat femurs was increased
82 by 33% with propranolol (16). In another study, intraperitoneal administration of the
83 cardio selective BB nebivolol, had a dose dependent increase in histologic osseous
84 healing in rat femur fractures stabilized with intramedullary Kirschner wires, whereas
85 cartilage formation was greater in the control group (17). However, rat osteotomy
86 healing with intraperitoneal propranolol administration in a third study did not change
87 final torsional strength or union rates, despite a nonsignificant increase in callus
88 strength at 5 weeks in the propranolol group (18).

89

90 The purpose of the present study was to evaluate the association between beta blocker
91 exposure and fracture healing in humans, given the evidence for anabolic osseous
92 effect in prior observational and animal studies.

93

94 **METHODS**

95 *Study Cohort*

96 A retrospective analysis of a convenience cohort drawn from Medicare beneficiaries
97 with a Part B (provider service) claim for back pain and/or osteoporosis from 2016-2019
98 was performed. Patients were included if they were over 65 years of age and had a Part
99 B inpatient or outpatient claim for a femur, tibia/fibula, forearm, or humerus fracture
100 identified by International Classification of Diseases and 10th Revision (ICD-10) codes
101 and Current Procedural Terminology codes (CPT) (Supplemental Table 1). From this
102 initial cohort, patients were then excluded if they were less than 65 years old at the time
103 of fracture, had Medicare through either the end stage renal disease (ESRD) or Social
104 Security Disability Insurance (SSDI) entitlement programs, were not enrolled in
105 Medicare Part D coverage, had follow-up of less than 1 year (e.g. fracture occurred in
106 2019), died within a year of fracture, had a concurrent or prior diagnosis of nonunion by
107 ICD-10 codes at the time of index fracture, or had insufficient 1 year claims history prior
108 to fracture to calculate comorbidity index. The cohort was screened for duplicate claims
109 which were excluded from final analysis. Patient demographics including age, sex, race
110 (simplified grouping as “White”, “Black”, or “Other”), and Charlson Comorbidity Index
111 (CCI) (19) were collected.

112

113 The primary outcome of this study was fracture status one year following index injury,
114 dichotomized as union or non-union. Non-union was identified in the final cohort using
115 CPT codes for nonunion and ICD-10 codes (Supplemental Table 1). A union of the
116 fracture was assumed if the beneficiary claims history did not include a non-union
117 diagnosis.

118

119 The analytical cohort was grouped based on exposure to beta blockers (supplemental
120 table 2) and statin medications for comparison and categorized as pre-fracture use only,
121 post-fracture use only, or both pre- and post-fracture exposure. Pre-fracture exposure
122 was defined as a prescription claim within 90 days prior to index fracture. Subgroup
123 analyses were also performed to evaluate differences in immediate post-fracture
124 exposure within 90 days of index fracture, difference in non-union within each specific
125 type of fracture, between selective vs. non-selective beta blockers, then beta blockers
126 were combined with statins, and based number of beta blocker (statin) prescriptions
127 filled served as a proxy for an exposure “dose-response”,

128

129 *Statistical Analysis*

130 Descriptive statistics were presented for patient demographics, fracture types, rates of
131 union and non-union, and medication use. Chi square and Student’s T-tests were
132 performed on categorical and continuous variables, respectively. Separate multivariable
133 logistic regression models with robust standard errors were then used to describe the
134 association between each medication class and fracture status at 1-year, both overall

135 and within each fracture type, controlling for age, sex, race and CCI. Similar logistic
136 regression models were used to examine the relationship between medication timing
137 and non-union while controlling for age, sex, race, CCI, and fracture type. Analyses
138 were conducted using Stata 17.0 MP (College Station, TX) accessed through
139 Medicare's Virtual Research Data Center, and presented as odds ratios with
140 hypotheses based on an alpha level of 0.001. A power analysis performed using a t
141 beta value of 0.80 indicated at least 5300 patients needed in each group to detect a 1%
142 difference in nonunion.

143

144 **RESULTS**

145 Starting with 1,079,157 extremity fractures, a total of 253,266 fractures met inclusion
146 criteria (Figure 1) with 85,114 femur fractures, 73,444 forearm fractures, 41,097
147 humerus fractures and 53,373 tibia or fibula fracture. Overall incidence of nonunion was
148 3.9%. The highest incidence of nonunion was observed among humerus fractures at
149 6.2%. Examining patient demographics, those diagnosed with nonunion were younger
150 by an average of 2 years ($p < .001$) and there was a higher proportion of males (21.3%
151 vs 17.8%, $p < .001$) (Table 2). There were no significant differences in race or CCI by
152 fracture outcome.

153

154 Exposure to beta blockers and statins was greater in males, patients with higher CCI,
155 and black race (Table 3).

156

157 After controlling for age, sex, race, comorbidity, and fracture type, the multivariable
158 model did not reveal a significant association between statin use and nonunion (OR
159 1.05 [95%CI 1.01 – 1.47] p-value=0.018). However, beta blockers were associated with
160 an 11% increase in nonunion diagnosis (OR 1.11 [95%CI 1.06-1.15] <0.001) regardless
161 of the number of prescriptions in the follow up period (Table 4). When excluding those
162 taking statins, the increase of nonunion among beta blocker users was 13% (OR 1.13
163 [95% CI 1.06-1.20]).

164

165 *Subgroup analysis:*

166 There was no obvious pattern in the likelihood of non-union based on the timing of beta-
167 blocker use relative to when the fracture occurred (Table 4). There was no difference
168 between selective (OR 1.12 [95%CI 1.07 – 1.17]), non-selective (OR 1.15 [95%CI 1.07
169 – 1.23]) or combined selective and non-selective (OR 1.15 [95%CI 0.99 – 1.34] BB
170 exposure on fracture status at 1 year (Table 5). All three categories had a higher risk
171 compared to the non-user group. Combined exposure of beta blocker and statin use
172 had a modest increase in nonunion (OR 1.19 [1.12-1.25 p<0.001] compared to non-
173 users but was not significantly more than taking either beta-blockers or statins alone
174 (Table 5). Neither a greater number of beta blockers prescription nor statin prescriptions
175 filled was associated with a greater likelihood of non-union (Table 4).

176

177 *Sensitivity analysis for unobserved confounding:*

178 We performed a sensitivity analysis to explore the possibility for unobserved
179 confounders to account for the higher risk of non-union found among beta-blocker users

180 at 1 year. By definition, a confounder is a factor associated with both the exposure
181 (beta blocker use) and the outcome (fracture non-union). A confounder sensitivity
182 analysis reports the magnitude that these associations require in order to nullify the
183 association that we observed. In our analysis, we found that a hypothetical unobserved
184 factor with an OR of 1.46 [or a lower CI limit of 1.31] for an association with both the
185 exposure and outcome was required to render our findings for beta blockers null. As
186 shown in Figure 2, a lesser association with the exposure requires an exponentially
187 greater association with the outcome (and vice versa).

188

189 **DISCUSSION**

190 Age-related bone loss is multi-factorial. The primary mechanism in both men and
191 women is gonadal sex steroid deficiency (20). While this change is more pronounced in
192 post-menopausal women, men also experience age related declines in bone density
193 (21, 22). In women this can be attenuated by hormone replacement therapy (HRT) (23-
194 25), due to HRT stimulation of growth hormone, TGFB and IGF-1 production (26-28).
195 Use of HRT to treat osteopenia or osteoporosis, however, is associated with increased
196 risk of cardiovascular events and breast cancer and is not recommended as first line
197 therapy (21). Geriatric patients also have increased sympathetic nervous system
198 activity, contributing to the higher risk of multi organ system pathophysiologic changes
199 with aging (29, 30) as well as age-related bone loss (14).

200

201 Multiple epidemiologic studies from 2000-2015 identified that patients taking BBs have
202 higher BMD and lower fracture risk (5-13). Preceding data from murine models also

203 found an anabolic effect of beta blockers on bone, with osteotomized rats exposed to
204 BB having greater callus formation and improved biomechanics compared to controls
205 (16, 17). The proposed mechanism of this observation is antagonism of normal skeletal
206 B2AR function in stimulating osteoclasts (31). While some animal studies similarly
207 found positive effects of beta blockers on osteotomy healing, there is competing basic
208 science evidence for this association across rodent models (18, 32-35). The aim of this
209 study was to further evaluate the association between beta blockers and fracture
210 fracture healing in humans.

211
212 In the present study, there was a modest but significant increase in the diagnosis of
213 nonunion among patients taking beta blockers. There was no difference between
214 cardioselective and nonselective beta blocker exposure. This finding is supported by a
215 previous database study, which also observed an association between cardiac
216 medications and diuretics and nonunion (36). The present study focused on beta
217 blocker use given the abundance of basic science research regarding the mechanism of
218 action of beta blockers in modulating osseous physiology. Notably, the study by
219 Buccheit et al., did not detect higher incidence of nonunion with steroid medications or
220 immunosuppressant exposure following fracture treatment.

221
222 Our findings contradict the existing literature regarding the osseoanabolic effect of beta
223 blockers and ongoing research regarding beta blockers as a potential primary
224 preventative agent for osteopenia and osteoporosis (2). However, it is important to
225 consider that adrenergic receptors have differential effects depending on the subtype

226 targeted by pharmacologic interventions. For example, the primary subtype expressed
227 in bone is β 2AR, which when stimulated by glucocorticoids results in lower bone
228 density, while co-treatment with propranolol was protective against bone loss (37). On
229 the other hand, beta-1 receptor knockout mice at 4 months have lower BMD, lower
230 bone volume, and trabecular volume when compared to both wild type (WT) and *Adrb2*
231 knockout mice (4), indicating that normal adrenergic beta-1 receptor function is
232 important for maintenance of bone volume and density in a murine model. Furthermore,
233 in the same study by Pierroz et al., *Adbr1b2^{-/-}* mice had persistent decreases in whole
234 body BMD up to 40 and 50 weeks of age, but this difference diminished as the mice
235 approached 60 weeks of age. Based on these findings, the authors propose that beta 2
236 signaling is higher in bone of wild type mice, but beta-1 signaling may be just as
237 important in the regulation of skeletal tissue.

238

239 Additionally, one must consider the condition where SNS activation is known to improve
240 fracture healing. In moderate and severe traumatic brain injury (TBI), fracture healing is
241 accelerated in both clinical studies and murine models (38-41). TBI results in several
242 pathophysiologic effects, but largely increases SNS activity. In an unpublished
243 independent study by Jahn et al., the authors found that increased NE-*Arb2* signaling
244 mediates TBI-induced skeletal manifestations in both bone remodeling and
245 regeneration. Furthermore, the study demonstrates that *Adrb2* plays an age-dependent
246 and pharmacologically targetable role in fracture healing by promoting callus
247 vascularization under conditions of increased sympathetic tone. The beneficial effect of
248 TBI on bone regeneration was also completely absent in mice lacking *Adrb2* (*medRxiv*

249 BIORXIV/2023/548550). These findings suggest an essential function of Adrb2 in
250 promoting bone repair and provide evidence that in a hyperadrenergic state, activity by
251 these receptors may be essential for normal bone healing.

252
253 The challenge in these large observational studies remains the difficulty in determining
254 the medication effect, versus a reflection of the patient's overall health status that is not
255 completely captured by comorbidity indices. The studies in question all use different
256 methods to control for comorbidities, which may confuse the results. It is also difficult to
257 discern if route of medication administration and age of the specimens may change the
258 central and peripheral effects of these medications. Finally, the present study is limited
259 as it is a convenience cohort of Medicare patients is not generalizable to the general
260 population.

261
262 **AUTHOR CONTRIBUTIONS**
263 Authorship note: LS and BM collaborated on study design, LM supervised the study, BM
264 performed statistical analysis, LS prepared the manuscript which was reviewed and
265 edited by the remaining authors.

266
267 **ACKNOWLEDEMENT**
268 Funding support provided by internal grant from the LS Peery MD Discovery Program of
269 the University of Utah's Department of Orthopaedics.

270

271

272 **REFERENCES**

- 273 1. Takeda S, et al. Leptin regulates bone formation via the sympathetic nervous system. *Cell*.
274 2002;111(3):305-317.
- 275 2. Karsenty G, and Khosla S. The crosstalk between bone remodeling and energy metabolism: A
276 translational perspective. *Cell Metab*. 2022;34(6):805-817.
- 277 3. Elefteriou F, et al. Leptin regulation of bone resorption by the sympathetic nervous system and
278 CART. *Nature*. 2005;434(7032):514-520.
- 279 4. Pierroz DD, et al. Deletion of β -adrenergic receptor 1, 2, or both leads to different bone
280 phenotypes and response to mechanical stimulation. *J Bone Miner Res*. 2012;27(6):1252-1262.
- 281 5. Schlienger RG, et al. Use of beta-blockers and risk of fractures. *JAMA*. 2004;292(11):1326-1332.
- 282 6. Pasco JA, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone
283 mineral density: Geelong Osteoporosis Study. *J Bone Miner Res*. 2004;19(1):19-24.
- 284 7. L. Rejnmark, et al. Fracture risk in perimenopausal women treated with beta-blockers *Calcif*
285 *Tissue Int*, 75 (2004), pp. 365-372
- 286 8. Wiens M, et al. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis
287 of observational studies. *J Intern Med*. 2006;260(4):350-362.
- 288 9. Graham S, et al. The effect of beta-blockers on bone metabolism as potential drugs under
289 investigation for osteoporosis and fracture healing. *Expert Opin Investig Drugs*. 2008;17(9):1281-
290 1299.
- 291 10. Yang S, et al Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis
292 Epidemiology Study. *Bone*. 2011;48(3):451-455.
- 293 11. Yang S, et al. Association between beta-blockers and fracture risk: a Bayesian meta-analysis.
294 *Bone*. 2012;51(5):969-974.
- 295 12. Toulis KA, et al. β -Adrenergic receptor antagonists and fracture risk: a meta-analysis of
296 selectivity, gender, and site-specific effects. *Osteoporos Int*. 2014;25(1):121-129.
- 297 13. Schlienger RG, et al. Use of beta-blockers and risk of fractures. *JAMA*. 2004;292(11):1326-1332.
- 298 14. Farr JN, et al. Relationship of sympathetic activity to bone microstructure, turnover, and plasma
299 osteopontin levels in women. *J Clin Endocrinol Metab*. 2012;97(11):4219-4227.

- 300 15. Khosla S, et al. Sympathetic β 1-adrenergic signaling contributes to regulation of human bone
301 metabolism. *J Clin Invest*. 2018;128(11):4832-4842.
- 302 16. Minkowitz B, et al. Effects of propranolol on bone metabolism in the rat. *J Orthop Res*.
303 1991;9(6):869-875.
- 304 17. Metineren H, et al. Effect of nebivolol on fracture healing: An experimental rat model. *Adv Clin*
305 *Exp Med*. 2017;26(6):919-923
- 306 18. Smitham P, et al. Low dose of propranolol does not affect rat osteotomy healing and callus
307 strength. *J Orthop Res*. 2014;32(7):887-893.
- 308 19. Quan H, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10
309 administrative data. *Medical Care* 2005. Nov; 43(11):1073-1077.
- 310 20. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. *Endocrinol*
311 *Metab Clin North Am*. 2005 Dec;34(4):1015-30, xi.
- 312 21. Khosla S, Amin S, Orwoll E. Osteoporosis in men. *Endocr Rev*. 2008;29(4):441-464.
- 313 22. Khosla S. Update in male osteoporosis. *J Clin Endocrinol Metab*. 2010;95(1):3-10.
- 314 23. Tobias JH, Compston JE. Does estrogen stimulate osteoblast function in postmenopausal
315 women?. *Bone*. 1999;24(2):121-124.
- 316 24. Lindsay R, et al. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence
317 for an increased bone mass after delayed onset of oestrogen treatment. *Lancet*.
318 1976;1(7968):1038–1041.
- 319 25. Genant HK, et al. Quantitative computed tomography of vertebral spongiosa: a sensitive method
320 for detecting early bone loss after oophorectomy. *Ann Intern Med*. 1982;97(5):699–705.
- 321 26. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in
322 experimental animals and the human. *Endocr Rev*. 1998;19(6):717-797.
- 323 27. Ernst M, Heath JK, Rodan GA. Estradiol effects on proliferation, messenger ribonucleic acid for
324 collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase
325 activity in osteoblastic cells from calvariae and long bones. *Endocrinology*. 1989;125(2):825-833.

- 326 28. Oursler MJ, et al. Modulation of transforming growth factor-beta production in normal human
327 osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. *Endocrinology*.
328 1991;129(6):3313-3320.
- 329 29. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal
330 women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*.
331 2002;288(3):321-333.
- 332 30. Pfeifer MA, et al. Differential changes of autonomic nervous system function with age in man. *Am*
333 *J Med*. 1983;75(2):249-258.
- 334 31. Jones PP, et al. Age-related increase in muscle sympathetic nerve activity is associated with
335 abdominal adiposity. *Am J Physiol*. 1997;272(6 Pt 1):E976-E980.
- 336 32. Bonnet N, et al. Protective effect of beta blockers in postmenopausal women: influence on
337 fractures, bone density, micro and macroarchitecture. *Bone*. 2007;40(5):1209-1216.
- 338 33. Suzuki A, et al. Catecholamines stimulate the proliferation and alkaline phosphatase activity of
339 MC3T3-E1 osteoblast-like cells. *Bone* 1998;23:197-203.
- 340 34. Zeman RJ, et al. Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated
341 hindlimbs. *Am J Physiol* 1991;261:E285-9.
- 342 35. Pataki A, et al. Anabolic effects of beta2-agonists, formoterol and salbutamol on cancellous bone
343 of ovariectomized rat. *Bone* 1996;9:A116.
- 344 36. Buchheit T, et al. Opioid exposure is associated with nonunion risk in a traumatically injured
345 population: An inception cohort study. *Injury*. 2018;49(7):1266-1271.
- 346 37. Ma Y, et al. β 2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of
347 glucocorticoids on bone. *Endocrinology*. 2011;152(4):1412-1422.
- 348 38. Perkins R, Skirving AP. Callus formation and the rate of healing of femoral fractures in patients
349 with head injuries. *J Bone Joint Surg Br*. 1987;69(4):521-524. doi:10.1302/0301-
350 620X.69B4.3611150
- 351 39. Yang C, et al. The effect of traumatic brain injury on bone healing from a novel exosome centered
352 perspective in a mice model. *J Orthop Translat*. 2021;30:70-81. Published 2021 Sep 23.

353 40. Bajwa NM, et al. Long-term Consequences of Traumatic Brain Injury in Bone Metabolism. Front
354 Neurol. 2018;9:115. Published 2018 Mar 5.

355 41. Locher RJ, et al. Traumatic brain injury and bone healing: radiographic and biomechanical
356 analyses of bone formation and stability in a combined murine trauma model. J Musculoskelet
357 Neuronal Interact. 2015;15(4):309-315.

358

359 **TABLE AND FIGURE LEGENDS**

360 Figure 1. Consort diagram of study cohort. Patients were excluded if they were eligible for
361 Medicare through social security disability (SSDI), end-stage renal disease (ESRD)
362 entitlements, had insufficient Part D pharmacy data or at least 1 year of claims data.

363

364 Table 1: Fracture union status at 1-year, within fracture type cohort.

365

366 Table 2: Demographic Characteristics between Medicare beneficiaries who did or did not
367 experience non-union within one year following fracture.

368

369 Table 3. Demographic Characteristics between Medicare beneficiaries based on medication
370 exposure.

371

372 Table 4: Association of select medications on non-union, controlling for age, sex, race, Charlson
373 comorbidity index (365-day lookback), and fracture type. (Prescription = Rx)

374

375 Table 5: Sub analysis of combined medication exposure and beta blocker class on non-union,
376 controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type.

377

378 Figure 2. Sensitivity analysis examining the relationship between potential unaccounted
379 confounders.

Figure 1. Consort diagram of study cohort. Patients were excluded if they were eligible for Medicare through social security disability (SSDI), end-stage renal disease (ESRD) entitlements, had insufficient Part D pharmacy data or at least 1 year of claims data.




Table 1. Fracture union status at 1-year, within fracture type cohort.

| Fracture Cohort | Union | Non union | Total |
|-----------------|----------------|--------------|--------|
| Femur | 82,059 (96.4%) | 3,055 (3.6%) | 85,114 |
| Forearm | 73,444 (97.2%) | 2,144 (2.8%) | 75,588 |
| Humerus | 38,566 (93.8%) | 2,531 (6.2%) | 41,097 |
| Fibula/Tibia | 51,041 (95.6%) | 2,332 (4.4%) | 53,373 |

Table 2. Demographic Characteristics between Medicare beneficiaries who did or did not experience non-union within one year following fracture.

| | Fracture outcome at 1 year | | | p-value |
|---------------------------------|----------------------------|------------------------|----------------------|---------|
| | Union (n=243,319) | Non-union (n=9,947) | Total (n=253,266) | |
| Age (mean) | 79.4 | 77.3 | 79.3 | <0.001 |
| Female, % | 82.2 | 77.7 | 82.0 | <0.001 |
| Race (3 groups), % | | | | |
| White | 91.6 | 91.6 | 91.6 | 0.407 |
| Black | 3.3 | 3.1 | 3.2 | |
| Other | 5.2 | 5.4 | 5.2 | |
| Comorbidity 365-day lookback, % | | | | |
| 0 | 21.7 | 21.4 | 21.7 | 0.739 |
| 1 | 20.6 | 20.5 | 20.6 | |
| 2 | 57.8 | 58.1 | 57.8 | |
| Medication use | | | | |
| Beta blocker, % | 45.0 | 47.3 | 45.1 | <0.001 |
| Statin, % | 53.3 | 56.6 | 53.4 | <0.001 |

Table 3. . Demographic Characteristics between Medicare beneficiaries based on medication exposure.

| | Beta Blocker | | p value | Statin | | p value |
|--|---------------|---------------|---------|---------------|---------------|---------|
| | No | Yes | | No | Yes | |
| N | 139,096 | 114,170 | | 117,921 | 135,345 | |
| Age, mean (sd) | 78.6 (8.1) | 80.2 (7.8) | | 79.9 (8.5) | 78.9 (7.6) | |
| Female, % | 83.1 | 80.7 | p<.001 | 84.8 | 79.6 | p<.001 |
| Race (3 groups), % | | | | | | |
| White | 91.6 | 91.6 | | 92.2 | 91 | |
| Black | 2.9 | 3.6 | | 3 | 3.4 | |
| Other | 5.5 | 4.8 | p<.001 | 4.8 | 5.5 | p<.001 |
| Comorbidity 365-day lookback, % | | | | | | |
| 0 | 27.8 | 14.2 | | 27.8 | 16.3 | |
| 1 | 22.9 | 17.6 | | 22.5 | 18.9 | |
| 2 | 49.2 | 68.2 | p<.001 | 49.7 | 64.8 | p<.001 |

Table 4. Association of select medications on non-union, controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type. (Prescription = Rx)

| Model | Factor | OR (95%CI) | Rate | p-value |
|--|--|--------------------|------------|---------|
| Non-union as a function of any exposure to medication within 1 year of fracture. | Beta-blocker | 1.11 (1.06 – 1.15) | 3.7 vs.3.4 | <0.001 |
| | Statin | 1.05 (1.01 – 1.10) | 3.6 vs 3.5 | 0.018 |
| Non-union as a function of beta blocker prescriptions filled (dose response) conditional on beta blocker use | 1-4 Rx | 1.00 (ref) | 4 | -- |
| | 5-6 Rx | 0.96 (0.89 – 1.03) | 3.8 | 0.258 |
| | 7+ Rx | 0.93 (0.87 – 1.00) | 3.7 | 0.045 |
| Non-union as a function of statin prescriptions filled (dose response) conditional on statin use | 1 -4 Rx | 1.00 (ref) | 4.1 | -- |
| | 5 Rx | 0.88 (0.83 – 0.95) | 3.6 | 0.001 |
| Non-union as a function pre and post-fracture beta blocker use | None | 1.00 (ref) | 3.5 | -- |
| | Pre fracture beta-blocker use only | 1.15 (0.97 – 1.35) | 4.0 | 0.110 |
| | Post fracture beta-blocker use only | 1.14 (1.07 – 1.22) | 3.9 | <0.001 |
| | Pre and post fracture beta-blocker use | 1.12 (1.07 – 1.17) | 3.9 | <0.001 |

Table 5. Sub analysis of combined medication exposure and beta blocker class on non-union, controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type.

| Model | Factor | OR (95%CI) | Rate | p-value |
|---|----------------------------------|--------------------|------|---------|
| Non-union as a function of interaction between beta-blocker use and statin use | None | 1.00 (Ref) | 3.4 | -- |
| | Beta-blocker | 1.13 (1.06 – 1.20) | 3.8 | <0.001 |
| | Statin | 1.08 (1.02 – 1.14) | 3.6 | 0.009 |
| | Beta-blocker & statin | 1.19 (1.12 – 1.25) | 3.9 | <0.001 |
| Non-union as a function of beta-blocker type (selective or non-selective), conditioned on use of beta blocker | Select beta-blocker | 1.00 (Ref) | 3.8 | - |
| | Non-select beta-blocker | 1.03 (0.96 – 1.11) | 3.9 | 0.355 |
| | Select & non-select beta-blocker | 1.04 (0.89 – 1.21) | 4 | 0.621 |

Figure 2. Sensitivity analysis examining the relationship between potential unaccounted confounders.

